XML 44 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 19, 2021
Jan. 25, 2021
Jul. 24, 2020
Apr. 30, 2020
Mar. 18, 2020
Nov. 09, 2018
Jun. 30, 2021
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Accumulated deficit             $ 106,816,303 $ 106,816,303   $ 99,135,961
Cash and cash equivalents             22,128,332 22,128,332   5,761,568
Net cash used in operating activities               9,242,939 $ (8,700,353)  
Proceeds from issuance of common stock, net of issuance costs               3,139,047 $ 1,941,095  
Reimbursement payment $ 14,000,000.0                  
Development payments 10,000,000.0                  
Current liabilities             35,147,054 35,147,054   $ 6,145,546
Deferred collaboration funding, short-term             22,191,292 22,191,292    
Liability related to securities class action and stockholder derivative actions settlements and legal costs             9,400,000 9,400,000    
Revenue               900,000    
Collaboration agreement amount 25,000,000.0                  
Correction of Error                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Accumulated deficit             2,939,898 2,939,898    
Current liabilities             2,939,898 2,939,898    
Deferred collaboration funding, short-term             2,939,898 2,939,898    
Adjustment to revenue resulting impact on net loss               (3,100,000)    
Revenue               (3,098,133)    
Deferred collaboration funding             3,100,000 3,100,000    
As Previously Reported                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Accumulated deficit             103,876,405 103,876,405    
Current liabilities             32,207,156 32,207,156    
Deferred collaboration funding, short-term             $ 19,251,394 19,251,394    
Revenue               $ 3,998,133    
Lincoln Park                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Issuance of common stock             0 200,000    
Issuance of common stock, price per share             $ 2.47 $ 2.47    
Proceeds from issuance of common stock gross               $ 500,000    
Proceeds from issuance of common stock, net of issuance costs               500,000    
Remaining obligation             $ 12,100,000 12,100,000    
Number of shares, company may sell on any single business day       50,000            
Maximum amount of Common stock at time of sale, per regular purchase       $ 1,000,000.0            
Issuance of common stock for commitment fee, shares       148,148            
Fair value of the commitment fee shares, recorded to general and administrative expense along with other costs       $ 400,000            
Cost, Product and Service [Extensible List]       General and Administrative            
Stock to be issued value on certain limitation and condition       $ 12,100,000            
Collaboration Agreement | Relief                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Upfront non-refundable payment received   $ 1,000,000.0                
Reimbursement payment 14,000,000.0 14,000,000.0                
Guarantee for substantive review food and drug application   0                
Milestone payment to be received 6,000,000.0 6,000,000.0                
Collaboration Agreement | Relief | First Development Payment                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Development payments subject new drug application             $ 10,000,000.0      
Collaboration Agreement | Relief | Second Development Payment                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Development payments subject new drug application $ 10,000,000.0 10,000,000.0           $ 10,000,000.0    
Weighted Average | Lincoln Park                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Issuance of common stock, price per share             $ 2.47 $ 2.47    
Maximum | Lincoln Park                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Shares value might be issued under agreement       $ 15,000,000.0            
Number of shares, company may sell on any single business day       100,000            
Maximum | Collaboration Agreement | Relief                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Development payments   $ 20,000,000.0                
At-the-Market Facility                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Issuance of common stock             0 877,107    
Proceeds from issuance of common stock gross               $ 2,800,000    
Common stock offering costs               200,000    
Proceeds from issuance of common stock, net of issuance costs               $ 2,600,000    
At-the-Market Facility | Weighted Average                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Issuance of common stock, price per share             $ 3.1692 $ 3.1692    
At-the-Market Facility | Maximum                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Aggregate offering price of common stock         $ 50,000,000.0 $ 50,000,000.0        
Private Placement | Directors, Officers and Employees                    
Organization Consolidation and Presentation of Financial Statement [Line Items]                    
Issuance of common stock     244,998              
Issuance of common stock, price per share     $ 3.50              
Proceeds from issuance of common stock, net of issuance costs     $ 900,000